AR053275A1 - Composicion de vacuna - Google Patents
Composicion de vacunaInfo
- Publication number
- AR053275A1 AR053275A1 ARP060101875A ARP060101875A AR053275A1 AR 053275 A1 AR053275 A1 AR 053275A1 AR P060101875 A ARP060101875 A AR P060101875A AR P060101875 A ARP060101875 A AR P060101875A AR 053275 A1 AR053275 A1 AR 053275A1
- Authority
- AR
- Argentina
- Prior art keywords
- vectors
- adenoviruses
- hiv
- virus
- procedures
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title 1
- 239000013598 vector Substances 0.000 abstract 6
- 241000700605 Viruses Species 0.000 abstract 4
- 241000701161 unidentified adenovirus Species 0.000 abstract 4
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 241001217856 Chimpanzee adenovirus Species 0.000 abstract 1
- 241001272567 Hominoidea Species 0.000 abstract 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000002255 vaccination Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
- C07K14/16—HIV-1 ; HIV-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- AIDS & HIV (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente se refiere a vectores virus que comprenden oligonucleotidos que codifican polipéptidos del VIH, más en particular aquellos en los que el vector virus es un adenovirus. En particular, tales adenovirus son adenovirus de primates no humanos tales como adenovirus de simios, más en particular adenovirus de chimpancé. En particular, la presente se refiere a vectores adenovirus que comprenden secuencias polinucleotídicas de VIH que codifican multiples antígenos de VIH diferentes, por ejemplo, dos, tres o más antígenos de VIH. La presente se refiere además a procedimientos para preparar los vectores virus, a los vectores virus producidos por los procedimientos y al uso de los vectores en medicina, en especial en vacunacion profiláctica o terapéutica.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US68038905P | 2005-05-12 | 2005-05-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR053275A1 true AR053275A1 (es) | 2007-04-25 |
Family
ID=36954770
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060101875A AR053275A1 (es) | 2005-05-12 | 2006-05-10 | Composicion de vacuna |
Country Status (20)
Country | Link |
---|---|
US (1) | US20090208515A1 (es) |
EP (1) | EP1880012B1 (es) |
JP (2) | JP5175178B2 (es) |
KR (1) | KR101451620B1 (es) |
CN (2) | CN103088060A (es) |
AR (1) | AR053275A1 (es) |
AU (1) | AU2006245920A1 (es) |
BR (1) | BRPI0608798A2 (es) |
CA (1) | CA2608316A1 (es) |
EA (1) | EA200702190A1 (es) |
ES (1) | ES2546330T3 (es) |
IL (1) | IL186828A (es) |
MA (1) | MA29458B1 (es) |
MX (1) | MX2007014038A (es) |
NO (1) | NO20075648L (es) |
PE (1) | PE20061372A1 (es) |
SG (1) | SG182173A1 (es) |
TW (1) | TW200716750A (es) |
WO (1) | WO2006120034A1 (es) |
ZA (1) | ZA200709518B (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA04004876A (es) | 2001-11-21 | 2004-07-30 | Univ Pennsylvania | Secuencias de acido nucleico y de aminoacido de adenovirus de simio, vectores que contienen los mismos y metodos de uso. |
US20090246220A1 (en) | 2006-08-28 | 2009-10-01 | Ertl Hildegund C J | Constructs for enhancing immune responses |
US9717788B2 (en) | 2007-03-02 | 2017-08-01 | Glaxosmithkline Biologicals Sa | Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant |
AU2008223951B2 (en) * | 2007-03-02 | 2014-03-27 | Glaxosmithkline Biologicals S.A. | Novel method and compositions |
DK2220242T3 (en) * | 2007-11-28 | 2017-03-27 | Univ Pennsylvania | ABE-ADENOVIRA OF GROUP B, SADV-28,27, -29, -32, -33 AND -35 AND APPLICATIONS THEREOF |
CN101883858B (zh) * | 2007-11-28 | 2015-07-22 | 宾夕法尼亚大学托管会 | 猿猴亚家族E腺病毒SAdV-39、-25.2、-26、-30、-37和-38及其应用 |
JP5661476B2 (ja) | 2008-03-04 | 2015-01-28 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | サルアデノウイルスSAdV−36、−42.1、−42.2および−44ならびにそれらの用途 |
EP3173096A1 (en) | 2011-04-06 | 2017-05-31 | Biovaxim Limited | Pharmaceutical compositions for preventing and/or treating an hiv disease in humans |
US8932607B2 (en) | 2012-03-12 | 2015-01-13 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
SI2825640T1 (sl) | 2012-03-12 | 2016-08-31 | Crucell Holland B.V. | Šarže rekombinantnega adenovirusa s spremenjenimi konci |
SG10201609511XA (en) | 2012-05-18 | 2016-12-29 | Univ Pennsylvania | Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof |
US9624510B2 (en) | 2013-03-01 | 2017-04-18 | The Wistar Institute | Adenoviral vectors comprising partial deletions of E3 |
KR102258564B1 (ko) * | 2013-03-14 | 2021-05-28 | 암젠 인크 | 메탈로프로테이나제 타입 3의 조직 억제제(timp-3)의 변이체, 조성물 및 방법 |
LT3271729T (lt) | 2015-03-18 | 2021-02-25 | Janssen Vaccines & Prevention B.V. | Rekombinantinių raiškos sistemų analizės būdai |
EP3283634B1 (en) | 2015-04-14 | 2019-05-22 | Janssen Vaccines & Prevention B.V. | Recombinant adenovirus expressing two transgenes with a bidirectional promoter |
EA038402B9 (ru) * | 2015-06-12 | 2021-09-22 | Глаксосмитклайн Байолоджикалс Са | Аденовирусные полинуклеотиды и полипептиды |
WO2017011336A1 (en) | 2015-07-10 | 2017-01-19 | E.&J. Gallo Winery | System and method for dispensing a beverage |
BR112018072865A2 (pt) | 2016-05-12 | 2019-04-30 | Janssen Vaccines & Prevention B.V. | promotor bidirecional potente e equilibrado |
MX2018015540A (es) | 2016-06-20 | 2019-04-11 | Janssen Vaccines & Prevention Bv | Promotor bidireccional potente y equilibrado. |
AU2017305176B2 (en) | 2016-08-01 | 2021-05-27 | The Wistar Institute Of Anatomy And Biology | Compositions and methods of replication deficient adenoviral vectors for vaccine applications |
CA3053212C (en) | 2017-02-09 | 2021-04-13 | Janssen Vaccines & Prevention B.V. | Potent and short promoter for expression of heterologous genes |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998010087A1 (en) * | 1996-09-06 | 1998-03-12 | Trustees Of The University Of Pennsylvania | Chimpanzee adenovirus vectors |
US6733993B2 (en) * | 2000-09-15 | 2004-05-11 | Merck & Co., Inc. | Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications |
EP1320621A4 (en) * | 2000-09-15 | 2005-11-23 | Merck & Co Inc | ADVANCED FIRST-GENE ADENOVIRAL VACCINES EXPRESSING CODON OPTIMIZATION OF THE GAG, POL AND NEF PROTEINS OF HIV-1 AND CHANGES THEREOF |
EP1409012B1 (en) * | 2001-06-22 | 2009-02-11 | The Wistar Institute Of Anatomy And Biology | Methods of inducing a cytotoxic immune response and recombinant simian adenovirus compositions useful therein |
EP1427826B1 (en) * | 2001-09-20 | 2011-04-20 | Glaxo Group Limited | HIV- RT-nef-Gag codon optimised DNA vaccines |
GB0225786D0 (en) * | 2002-11-05 | 2002-12-11 | Glaxo Group Ltd | Vaccine |
GB0225788D0 (en) * | 2002-11-05 | 2002-12-11 | Glaxo Group Ltd | Vaccine |
CA2539864A1 (en) * | 2003-09-24 | 2005-04-07 | Oxxon Therapeutics Limited | Hiv pharmaccines |
GB2406336A (en) * | 2003-09-24 | 2005-03-30 | Oxxon Pharmaccines Ltd | HIV Pharmaccines |
GB0417494D0 (en) * | 2004-08-05 | 2004-09-08 | Glaxosmithkline Biolog Sa | Vaccine |
-
2006
- 2006-05-10 CN CN2013100023418A patent/CN103088060A/zh active Pending
- 2006-05-10 SG SG2012041687A patent/SG182173A1/en unknown
- 2006-05-10 US US11/913,952 patent/US20090208515A1/en not_active Abandoned
- 2006-05-10 MX MX2007014038A patent/MX2007014038A/es active IP Right Grant
- 2006-05-10 EA EA200702190A patent/EA200702190A1/ru unknown
- 2006-05-10 AR ARP060101875A patent/AR053275A1/es unknown
- 2006-05-10 CN CNA2006800162796A patent/CN101384722A/zh active Pending
- 2006-05-10 BR BRPI0608798-1A patent/BRPI0608798A2/pt not_active IP Right Cessation
- 2006-05-10 KR KR1020077029093A patent/KR101451620B1/ko not_active IP Right Cessation
- 2006-05-10 EP EP06743016.5A patent/EP1880012B1/en active Active
- 2006-05-10 ES ES06743016.5T patent/ES2546330T3/es active Active
- 2006-05-10 CA CA002608316A patent/CA2608316A1/en not_active Abandoned
- 2006-05-10 JP JP2008510517A patent/JP5175178B2/ja not_active Expired - Fee Related
- 2006-05-10 PE PE2006000493A patent/PE20061372A1/es not_active Application Discontinuation
- 2006-05-10 WO PCT/EP2006/004854 patent/WO2006120034A1/en active Application Filing
- 2006-05-10 AU AU2006245920A patent/AU2006245920A1/en not_active Abandoned
- 2006-05-10 TW TW095116578A patent/TW200716750A/zh unknown
-
2007
- 2007-10-22 IL IL186828A patent/IL186828A/en not_active IP Right Cessation
- 2007-11-05 ZA ZA2007/09518A patent/ZA200709518B/en unknown
- 2007-11-06 NO NO20075648A patent/NO20075648L/no not_active Application Discontinuation
- 2007-11-20 MA MA30386A patent/MA29458B1/fr unknown
-
2012
- 2012-08-24 JP JP2012185395A patent/JP2013046613A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
MX2007014038A (es) | 2008-02-11 |
ZA200709518B (en) | 2014-01-29 |
EP1880012B1 (en) | 2015-07-08 |
JP2008539746A (ja) | 2008-11-20 |
IL186828A (en) | 2015-06-30 |
SG182173A1 (en) | 2012-07-30 |
KR20080021659A (ko) | 2008-03-07 |
CA2608316A1 (en) | 2006-11-16 |
EA200702190A1 (ru) | 2008-04-28 |
PE20061372A1 (es) | 2007-01-16 |
BRPI0608798A2 (pt) | 2011-03-15 |
CN103088060A (zh) | 2013-05-08 |
US20090208515A1 (en) | 2009-08-20 |
JP5175178B2 (ja) | 2013-04-03 |
AU2006245920A1 (en) | 2006-11-16 |
TW200716750A (en) | 2007-05-01 |
IL186828A0 (en) | 2008-02-09 |
CN101384722A (zh) | 2009-03-11 |
EP1880012A1 (en) | 2008-01-23 |
NO20075648L (no) | 2008-02-07 |
JP2013046613A (ja) | 2013-03-07 |
WO2006120034A1 (en) | 2006-11-16 |
WO2006120034A8 (en) | 2007-11-15 |
ES2546330T3 (es) | 2015-09-22 |
MA29458B1 (fr) | 2008-05-02 |
KR101451620B1 (ko) | 2014-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR053275A1 (es) | Composicion de vacuna | |
BR112018004242A2 (pt) | composições de vacina que possuem estabilidade e imunogenicidade aumentadas | |
BR112016020688A2 (pt) | Composições úteis no tratamento da deficiência da ornitina transcarbamilase (otc) | |
BR112018007525A2 (pt) | composições imunogênicas de circovírus suíno tipo 3 e métodos de produzir e usar as mesmas | |
ECSP10010287A (es) | Vectores de virus oncolíticos de viruela | |
BR112019024747A2 (pt) | formulações de dose fixa | |
NO20090194L (no) | Rekombinant viral vaksine | |
BR112014009526B8 (pt) | Composição de vacina compreendendo pd-l1, kit de partes compreendendo tal composição e uso dos mesmos para tratar ou prevenir câncer | |
MX2010008468A (es) | Acidos nucleicos de la formula (i) (nug1xmgnnv)a y derivados de los mismos como un agente/adyuvante inmunoestimulante. | |
ECSP10010288A (es) | Vectores de virus oncolíticos de viruela | |
AR088622A1 (es) | 18-METIL-6,7-METILEN-3-OXO-17-PREGN-4-EN-21,17b-CARBOLACTONA, PREPARADOS FARMACEUTICOS QUE CONTIENEN LOS COMPUESTOS MENCIONADOS Y SU USO EN LA TERAPIA DE LA ENDOMETRIOSIS | |
JP2014534202A5 (es) | ||
BR112012033767A2 (pt) | processo para produzir um vírus de interesse, para remover um agente adventício, e para remover um agente adventício, vírus,e, composição imunogênica ou vacina. | |
BR112018068078A2 (pt) | vacinas de circovírus suíno tipo 2 (pcv2) quimérico | |
BR112012029975A2 (pt) | peptídeo como medicamento, em particular para o tratamento do câncer. | |
AR073170A1 (es) | Vacunas de poliproteinas recombinantes para el tratamiento y diagnostico de leishmaniasis | |
ECSP12012031A (es) | Composición farmacéutica que comprende oligopéptidos | |
NZ608143A (en) | Recombinant modified vaccinia virus ankara (mva) influenza vaccine | |
BR112015008417A8 (pt) | composição imunogênica, vacina, e, uso de uma composição imunogênica | |
CL2012000447A1 (es) | Composición o vacuna que comprende un vector viral de un paramixovirus aviar 8 (apmv-8) recombinante; método para producir dicho vector; y uso para preparar medicamento útil para inducir una respuesta inmunológica. | |
MX2015007753A (es) | Composicion de vacunas para sujetos intactos. | |
AR089616A1 (es) | Monomeros de bis-glicidilmetacrilatos para la formulacion de resinas compuestas para uso dental, metodo para la preparacion de dichos monomeros bis-glicidilmetacrilatos, formulacion de resinas de restauracion dental directa que los comprenden y usos de dichos monomeros | |
IN2015DN02335A (es) | ||
BR112015031226A2 (pt) | Composição de vacina, e, uso da composição de vacina | |
ES2497341R1 (es) | Catalizador soportado sobre alúmina para su uso en la polimerización de olefinas y método para su preparación |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |